Spironolactone and canrenoate‐K: Relative potency at steady state
- 1 May 1977
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 21 (5), 602-609
- https://doi.org/10.1002/cpt1977215602
Abstract
Relative dose ratios of the mineralocorticoid antagonists spironolactone (100 mg and 200 mg daily) and canrenoate-K (200 mg daily) at steady state were defined in six healthy subjects with fiudrocortisone as the mineralocorticoid agonist. The urine log 10 Na/K responses during spironolactone treatments were consistent with the law of mass action. The potency of canrenoate-K was 0.68 (95% C.L. 0.53 to 0.89) that of spironolactone on a weight basis. Approximately 72% of the renal antimineralocorticoid activity of spironolactone could be attributed to the metabolite canrenone. The results at steady state are contrasted with those of a previous study comparing single doses of spironolactone and canrenoate-K.This publication has 10 references indexed in Scilit:
- Spironolactone and potassium canrenoate in normal manClinical Pharmacology & Therapeutics, 1976
- PHARMACOLOGICAL RECEPTORS1968
- Relationship of Plasma Aldadiene Levels and Antimineralocorticoid Effects of Spironolactone in the LaboratoryExperimental Biology and Medicine, 1964
- PHARMACOLOGICAL PROPERTIES OF MINERALOCORTICOID ANTAGONIST ( SC-14266 )1964
- QUANTITATION OF MINERALOCORTICOID ACTIVITY AND ANTAGONISM IN NORMAL SUBJECTS1963
- HUMAN ASSAY OF ELECTROLYTE-ACTIVE STEROIDS AND THEIR ANTAGONISTS1962
- FLUORIMETRIC METHOD FOR DETERMINATION OF A MAJOR SPIRONOLACTONE (ALDACTONE) METABOLITE IN HUMAN PLASMA1962
- Determination of Creatinine by Means of Automatic Chemical AnalysisAmerican Journal of Clinical Pathology, 1961
- BLOCKING THE RENAL ELECTROLYTE EFFECTS OF MINERALOCORTICOIDS WITH AN ORALLY ACTIVE STEROIDAL SPIROLACTONEEndocrinology, 1960
- BIOASSAY OF ADRENAL CORTICAL STEROIDS ON THE BASIS OF ELECTROLYTE EXCRETION BY RATS: EFFECTS OF 11-DESOXY and 11-OXY-STEROIDS1Endocrinology, 1954